CMMB
Chemomab Therapeutics Ltd.·Healthcare
1.67
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $1.3552W H: $5.88
CMMB NEWS
globenewswire.com
Mar 19
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.
globenewswire.com
Feb 17
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 36 th Annual Healthcare Life Sciences Conference on February 26, 2026.
defenseworld.net
Jan 15
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest
Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ: CMMB - Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 18,047 shares, a growth of 100.7% from the December 15th total of 8,994 shares. Approximately 0.3% of the company's shares are short sold. Based
